Evidence map›Paper›PMID 33569321›Full record

ArticleTranslational lung cancer research2021

Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults.

Xuesi Dong, Jieyu He, Lijuan Lin, Ying Zhu, Chao Chen, Li Su, Yang Zhao, Ruyang Zhang, Yongyue Wei, Feng Chen and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Xuesi DongDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Jieyu HeDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Lijuan LinDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Ying ZhuDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Chao ChenDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Li SuDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Yang ZhaoDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Ruyang ZhangDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Yongyue WeiDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Feng ChenDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Nanjing Medical University · CNHarvard University · USJiangsu Cancer Hospital · CNMassachusetts General Hospital · USNanjing General Hospital of Nanjing Military Command · CNSoutheast University · CN

Funding

Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Molecular and Genetic Analysis of Lung Cancer SurvivalR01CA092824 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2002 to 2013
$5.9M
NCI NIH HHS R01 CA092824NCI NIH HHS U01 CA209414NIEHS NIH HHS P30 ES000002
6 · The paper itself

Abstract

backgroundChemoprevention of cancer with aspirin is controversial as a primary prevention strategy. We sought to investigate the association between aspirin frequency and risk of lung cancer in The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

methodsUsing data from 101,722 participants in PLCO, we used a Cox regression model coupling with propensity score to detect the association between aspirin frequency and lung cancer risk.

resultsHigh-frequency aspirin use significantly increased risk of lung cancer by 28% compared to no use (HR =1.28; 95% CI, 1.14-1.45; P=3.37×10

conclusionsHigh-frequency aspirin use is associated with the increased risk of lung cancer. Current smoker or people with age <76 years and bodyweight <80 kg should be more cautious to high-frequency aspirin use for lung cancer chemoprevention. This study provides a new insight for lung cancer chemoprevention.

Indexed as

ageAspirinbodyweightlung cancerrisk

Identifiers

PMID33569321
PMCPMC7867785
OpenAlexW3105175575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.